Recent advances in topical therapeutics for vitreoretinal diseases

Jonathan Gibson; Samantha McGinnigle

Recent advances in topical therapeutics for vitreoretinal diseases

Jonathan Gibson
, Samantha McGinnigle

Research output: Contribution to journal › Article › peer-review

239 Downloads (Pure)

Abstract

Eye drops are convenient for patients, but achieving therapeutic doses and maintaining sustained drug release without frequent re-application
to treat diseases of the retina has been largely unsuccessful. Topical administration of drugs is hindered by the anatomy, physiology, and biochemistry of the eye and its highly effective defence mechanisms. Advances in nanotechnology have led to the experimental use of topical permeation-enhancing liposomes, emulsions, and microspheres to enhance absorption and penetration of drugs across membranes; allow controlled release of the drug; and to target drugs at distinct tissues to allow sufficient local bioavailability. In the near future it is hoped that improved technologies may provide means of sustained topical drug delivery for retinal therapy, with improved side-effect profiles and reduced cost compared with currently available clinical treatments.

Original language	English
Pages (from-to)	2-7
Number of pages	6
Journal	US Ophthalmic Review
Volume	8
Issue number	1
Publication status	Published - 2015

Bibliographical note

This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

nanoparticles
eye drops
diabetes
retinal disorders
topical ocular delivery
liposomes

Access to Document

Recent advances in topical therapeutics for vitreoretinal diseases
This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.
Final published version, 77.9 KBLicence: CC BY-NC 3.0

http://www.touchophthalmology.com/articles/recent-advances-topical-therapeutics-vitreoretinal-diseases

Cite this

@article{963232f56c99441d9bbf4dbabe0c279c,

title = "Recent advances in topical therapeutics for vitreoretinal diseases",

abstract = "Eye drops are convenient for patients, but achieving therapeutic doses and maintaining sustained drug release without frequent re-application to treat diseases of the retina has been largely unsuccessful. Topical administration of drugs is hindered by the anatomy, physiology, and biochemistry of the eye and its highly effective defence mechanisms. Advances in nanotechnology have led to the experimental use of topical permeation-enhancing liposomes, emulsions, and microspheres to enhance absorption and penetration of drugs across membranes; allow controlled release of the drug; and to target drugs at distinct tissues to allow sufficient local bioavailability. In the near future it is hoped that improved technologies may provide means of sustained topical drug delivery for retinal therapy, with improved side-effect profiles and reduced cost compared with currently available clinical treatments.",

keywords = "nanoparticles, eye drops, diabetes, retinal disorders, topical ocular delivery, liposomes",

author = "Jonathan Gibson and Samantha McGinnigle",

note = "This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. ",

year = "2015",

language = "English",

volume = "8",

pages = "2--7",

journal = "US Ophthalmic Review",

issn = "1756-1760",

number = "1",

}

TY - JOUR

T1 - Recent advances in topical therapeutics for vitreoretinal diseases

AU - Gibson, Jonathan

AU - McGinnigle, Samantha

N1 - This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

PY - 2015

Y1 - 2015

N2 - Eye drops are convenient for patients, but achieving therapeutic doses and maintaining sustained drug release without frequent re-application to treat diseases of the retina has been largely unsuccessful. Topical administration of drugs is hindered by the anatomy, physiology, and biochemistry of the eye and its highly effective defence mechanisms. Advances in nanotechnology have led to the experimental use of topical permeation-enhancing liposomes, emulsions, and microspheres to enhance absorption and penetration of drugs across membranes; allow controlled release of the drug; and to target drugs at distinct tissues to allow sufficient local bioavailability. In the near future it is hoped that improved technologies may provide means of sustained topical drug delivery for retinal therapy, with improved side-effect profiles and reduced cost compared with currently available clinical treatments.

AB - Eye drops are convenient for patients, but achieving therapeutic doses and maintaining sustained drug release without frequent re-application to treat diseases of the retina has been largely unsuccessful. Topical administration of drugs is hindered by the anatomy, physiology, and biochemistry of the eye and its highly effective defence mechanisms. Advances in nanotechnology have led to the experimental use of topical permeation-enhancing liposomes, emulsions, and microspheres to enhance absorption and penetration of drugs across membranes; allow controlled release of the drug; and to target drugs at distinct tissues to allow sufficient local bioavailability. In the near future it is hoped that improved technologies may provide means of sustained topical drug delivery for retinal therapy, with improved side-effect profiles and reduced cost compared with currently available clinical treatments.

KW - nanoparticles

KW - eye drops

KW - diabetes

KW - retinal disorders

KW - topical ocular delivery

KW - liposomes

M3 - Article

SN - 1756-1760

VL - 8

SP - 2

EP - 7

JO - US Ophthalmic Review

JF - US Ophthalmic Review

IS - 1

ER -

Recent advances in topical therapeutics for vitreoretinal diseases

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this